CGEM - Cullinan Management

-

$undefined

N/A

(N/A)

Cullinan Management NasdaqGS:CGEM Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Location: One Main Street, Cambridge, MA, 02142, United States | Website: https://cullinantherapeutics.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

210.3M

Cash

303.8M

Avg Qtr Burn

-37.55M

Short % of Float

15.35%

Insider Ownership

4.55%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Zipalertinib Details
Non-small cell lung carcinoma

Phase 3

Update

Zipalertinib Details
Non-small cell lung carcinoma

Phase 1/2

Data readout

Phase 1

Data readout

CLN-049 (FLT3xCD3) Details
Relapsed/refractory acute myeloid leukemia, Acute myeloid leukemia

Phase 1

Update

CLN-978 (CD19xCD3) Details
Non-Hodgkin lymphoma, Blood cancer, Cancer

Phase 1

Update

Phase 1

Update

Phase 1

Initiation

CLN-978 (CD19xCD3) Details
Autoimmune disease, Systemic lupus erythematosus

Phase 1

Initiation

CLN-978 (CD19xCD3) Details
Rheumatoid Arthritis

Phase 1

Initiation

CLN-978 (CD19xCD3) Details
Sjögren’s disease (SjD)

Phase 1

Initiation

Failed

Discontinued